首页> 美国卫生研究院文献>Viruses >Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4
【2h】

Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4

机译:在持续感染柯萨奇病毒B4的人类胰腺细胞培养过程中耐氟西汀的变异体的出现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

This study reports the antiviral activity of the drug fluoxetine against some enteroviruses (EV). We had previously established a model of persistent coxsackievirus B4 (CVB4) infection in pancreatic cell cultures and demonstrated that fluoxetine could clear the virus from these cultures. We further report the emergence of resistant variants during the treatment with fluoxetine in this model. Four independent persistent CVB4 infections in Panc-1 cells were treated with fluoxetine. The resistance to fluoxetine was investigated in an acute infection model. The 2C region, the putative target of fluoxetine antiviral activity, was sequenced. However, Fluoxetine treatment failed to clear CVB4 in two persistent infections. The resistance to fluoxetine was later confirmed in HEp-2 cells. The decrease in viral titer was significantly lower when cells were inoculated with the virus obtained from persistently infected cultures treated with fluoxetine than those from susceptible mock-treated cultures (0.6 log TCID50/mL versus 4.2 log TCID50/mL, p < 0.0001). Some previously described mutations and additional ones within the 2C protein were found in the fluoxetine-resistant isolates. The model of persistent infection is an interesting tool for assessing the emergence of variants resistant to anti-EV molecules. The resistance of EV strains to fluoxetine and its mechanisms require further investigation.
机译:这项研究报告了氟西汀对某些肠病毒(EV)的抗病毒活性。我们先前已经建立了在胰腺细胞培养物中持续感染柯萨奇B4(CVB4)的模型,并证明氟西汀可以从这些培养物中清除病毒。我们进一步报告了在该模型中用氟西汀治疗期间耐药变异的出现。 Panc-1细胞中的四个独立的持续性CVB4感染用氟西汀治疗。在急性感染模型中研究了氟西汀的耐药性。对2C区(氟西汀抗病毒活性的假定靶标)进行了测序。但是,氟西汀治疗未能清除两次持续感染中的CVB4。后来在HEp-2细胞中证实了对氟西汀的耐药性。当用从用氟西汀处理的持续感染的培养物中获得的病毒接种细胞时,病毒滴度的降低明显低于从易感模拟处理的培养物中获得的病毒(0.6 log TCID50 / mL对4.2 log TCID50 / mL,p <0.0001)。在耐氟西汀的分离物中发现了一些先前描述的突变以及2C蛋白中的其他突变。持续感染模型是评估抗EV分子耐药变体出现的有趣工具。 EV菌株对氟西汀的耐药性及其机制尚需进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号